

**Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial**

Susan Halabi et al. *Kidney Cancer Journal*, 19(3), 64-72, 2021

DOI.org/10.52733/kcj19n3-a1

**SUPPLEMENTARY DATA**

**TABLES.**

**Supplementary Table 1.** Summary of 5 tissue biomarkers analyzed in the present study using immunohistochemistry according to antibody source, isotype, dilution, antigen retrieval method, and clinical thresholds examined.

| <b>Biomarker</b>                | <b>Antibody Source</b>      | <b>Antibody Isotype</b> | <b>Dilution Factor</b> | <b>Antigen Retrieval Method</b> | <b>Primary Threshold</b> | <b>Secondary Threshold</b> |
|---------------------------------|-----------------------------|-------------------------|------------------------|---------------------------------|--------------------------|----------------------------|
| <b>pAkt (S473)</b>              | Cell Signaling Technologies | Rabbit mAb              | 1:50                   | pH 9.0 EDTA                     | 0 vs. 1-3                | 0-1 vs. 2-3                |
| <b>pS6 (S235/236)</b>           | Cell Signaling Technologies | Rabbit mAb              | 1:100                  | pH 9.0 EDTA                     | 0 vs. 1-3                | 0-1 vs. 2-3                |
| <b>HIF-1<math>\alpha</math></b> | Abcam                       | Rabbit mAb              | 1:200                  | pH 9.0 EDTA                     | 0 vs. 1-3                | 0-1 vs. 2-3                |
| <b>c-kit</b>                    | Dako                        | Rabbit pAb              | Pre-dilute             | pH 6.1 Citrate                  | 0 vs. 1-3                | 0-1 vs. 2-3                |
| <b>c-MET</b>                    | Novus                       | Mouse mAb               | 1:50                   | pH 6.1 Citrate                  | 0 vs. 1-3                | 0-1 vs. 2-3                |